CAPS and metastatic neoplasm: Using the “HGSOC Progression” TMA, we compared the percentage of 42 patient-matched primary, synchronous metastatic, and metachronous/recurrent metastatic tumors for the presence of FOXJ1+ and/or CAPS+ cells.